The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.
Video content above is prompted by the following questions:
- How has the emergence of CAR T-cell therapy impacted the treatment paradigm for relapsed/refractory multiple myeloma?
- Does this therapy address an unmet need in R/R MM?
- How do you manage patients who may not meet the eligibility criteria for CAR T-cell therapy but still have a significant unmet need for effective treatment options?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
